SCHEMBL6607970

SCHEMBL6607970

CC(C)(C)OC(=O)Nc1cnccc1I.CN(C)CC#Cc1ccncc1NC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
CYP17A1 P05093 4/20 0.36
CYP2A6 P11509 1/20 0.35
PDE5A O76074 1/20 0.33
PDE4A P27815 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE1C Q14123 1/20 0.33
PDE3A Q14432 1/20 0.33
KCNQ4 P56696 1/20 0.33
KCNQ5 Q9NR82 1/20 0.33
IDO1 P14902 2/20 0.33
CYP3A4 P08684 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035878 0.94 NAMPT (0.41) NAMPTHTR1DHTR1BCYP17A1CYP2A6
SCHEMBL6596669 0.87 CYP17A1 (0.37) NAMPTCYP17A1CYP3A4RAB9ATRPV1
SCHEMBL1635061 0.82 NAMPT (0.47) NAMPTCYP17A1RAB9A
SCHEMBL30759207 0.82 NAMPT (0.47) NAMPTCYP17A1RAB9A
SCHEMBL6606922 0.81 HTR1D (0.33) NAMPTHTR1DHTR1BCYP17A1CYP2A6
SCHEMBL6034096 0.78 CYP2A6 (0.44) HTR1DHTR1BCYP2A6CYP3A4
SCHEMBL6035359 0.74 ALDH1A1 (0.36) NAMPTHTR1DHTR1BCYP2A6PDE5A
SCHEMBL17347511 0.74 CYP17A1 (0.37) NAMPTCYP17A1CYP3A4RAB9A
SCHEMBL18848179 0.73 ALDH1A1 (0.41) NAMPTCYP17A1CYP3A4TRPV1
SCHEMBL4037373 0.72 NAMPT (0.47) NAMPTCYP17A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 EP disclosed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 WO disclosed